Immunome Yönetim

Yönetim kriter kontrolleri 1/4

Immunome CEO'su Clay Siegall, Oct2023 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 15.65M olup, şirket hissesi ve opsiyonları dahil olmak üzere 1% maaş ve 99% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.83% ine doğrudan sahiptir ve bu hisseler $ 5.76M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.2 yıl ve 3.5 yıldır.

Anahtar bilgiler

Clay Siegall

İcra Kurulu Başkanı

US$15.6m

Toplam tazminat

CEO maaş yüzdesi	1.0%
CEO görev süresi	1.2yrs
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	1.2yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Clay Siegall'un ücretlendirmesi Immunome'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$305m
Jun 30 2024	n/a	n/a	-US$263m
Mar 31 2024	n/a	n/a	-US$232m
Dec 31 2023	US$16m	US$163k	-US$107m

Tazminat ve Piyasa: Clay 'nin toplam tazminatı ($USD 15.65M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.30M ).

Tazminat ve Kazançlar: Clay şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Clay Siegall (63 yo)

1.2yrs

Görev süresi

US$15,648,944

Tazminat

Dr. Clay B. Siegall, Ph D., serves as Independent Chairman since December 13, 2023 at Tourmaline Bio, Inc. He served as Chief Executive Officer & President of Morph Immune, Inc. from March 2023 until Octob...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Clay Siegall	President	1.2yrs	US$15.65m	0.83% $ 5.8m
Jack Higgins	Chief Scientific Officer	1.2yrs	US$2.17m	0.022% $ 149.9k
Robert Lechleider	Chief Medical Officer	1.2yrs	US$3.22m	0.025% $ 175.1k
Max Rosett	Executive VP of Operations	1.2yrs	Veri yok	0.076% $ 526.0k
Philip Tsai	Chief Technical Officer	no data	Veri yok	0.034% $ 232.6k
Sandra Stoneman	Chief Legal Officer	4.2yrs	US$1.64m	0.0089% $ 61.6k
Bruce Turner	Chief Strategy Officer	1.2yrs	Veri yok	0.068% $ 468.7k
Kinney Horn	Chief Business Officer	less than a year	Veri yok	Veri yok
Roee Shahar	Executive Vice President of Commercial	less than a year	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: IMNM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Clay Siegall	President	1.2yrs	US$15.65m	0.83% $ 5.8m
Louis Weiner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Philip Wagenheim	Director	7yrs	US$59.23k	0.63% $ 4.4m
George Prendergast	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Isaac Barchas	Lead Independent Director	1.2yrs	US$296.59k	0.0083% $ 57.5k
James Boylan	Independent Director	1.2yrs	US$294.75k	0% $ 0
Andrew Badley	Member of COVID-19 Advisory Board	3.5yrs	Veri yok	Veri yok
Carol Schafer	Independent Director	less than a year	Veri yok	0% $ 0
William Strohl	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Henderson	Member of COVID-19 Advisory Board	4.3yrs	Veri yok	Veri yok
Shmuel Shoham	Member of COVID-19 Advisory Board	4.3yrs	Veri yok	Veri yok
Susan Weiss	Member of COVID-19 Advisory Board	4.3yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMNM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/20 02:31
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Immunome, Inc. 9 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Lut Ming Cheng	Cantor Fitzgerald & Co.
Michael Schmidt	Guggenheim Securities, LLC
Lut Ming Cheng	J.P. Morgan

Immunome Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

President recently bought US$962k worth of stock

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Recent updates

Immunome: A Recently Acquired Lead Asset And A Small Market

New minor risk - Share price stability

President recently bought US$962k worth of stock

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01